Nu-Med Plus, Inc. Reveals Plan to Develop Clinical Inhaled Nitric Oxide Device Using Inexpensive Technology

SALT LAKE CITY, UT--(Marketwired - Jul 21, 2015) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announced it has begun development of an inhaled Nitric Oxide clinical device designed for low cost use in medical office environments.

Nitric Oxide (NO) is a medically essential gas that is presently used in neonate Hypoxia therapy, and which may have additional applications for a variety of other diseases and complications which are currently being researched. It is anticipated that this Nitric Oxide clinical device will have the capability of delivering high-purity, inhaled NO in single treatments, using proprietary formulation, to generate controlled flow through a nasal cannula, face mask or appropriate therapy attachments.

Jeff Robins, President and CEO of Nu-Med Plus, Inc. commented, "We are thrilled to be moving forward with the expansion of our product candidates using our conversion technology, which will allow for single treatments and controlled doses of inhaled NO in treatment centers along with medical and urgent care clinics."

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. designs, develops and markets innovative medical devices for use in patient treatment. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com.

Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.